When do biologic drug patents expire and when will biosimilars launch?

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Centocor Ortho Biotech Products, L.p.	ORTHOCLONE OKT3	muromanab-cd3	Injection	103463	09/14/1992	⤷ Try a Trial	2026-04-27
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994	⤷ Try a Trial	2026-04-27
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2026-04-27
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2026-04-27
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997	⤷ Try a Trial	2026-04-27
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998	⤷ Try a Trial	2026-04-27
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003	⤷ Try a Trial	2026-04-27
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Title:	Methods and compositions for antibody therapy
Abstract:	Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc.gamma.RIIA polymorphism, or a Fc.gamma.RIIIA polymorphism, or both an Fc.gamma.RIIA polymorphism and a Fc.gamma.RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject\'s Fc.gamma.RIIA polymorphism, or Fc.gamma.RIIIA polymorphism, or both the Fc.gamma.RIIA polymorphism and the Fc.gamma.RIIIA polymorphism.
Inventor(s):	Ramakrishnan; Vijay (Palo Alto, CA)
Assignee:	PIKAMAB, Inc. (Palo Alto, CA)
Application Number:	12/298,661
Patent Claims:	see list of patent claims

Patent: 8,592,149